Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report

Naik,Radheshyam; Khan,Mujtaba  A.

doi:10.3892/mco.2017.1147

Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report

Authors:
- Radheshyam Naik
- Mujtaba A. Khan
View Affiliations

Affiliations: Department of Medical Oncology, HCG Hospital, Bangalore, Karnataka 560027, India, Department of Medical Affairs, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 382210, India
Published online on: February 2, 2017 https://doi.org/10.3892/mco.2017.1147
Pages: 341-343
Copyright: © Naik et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Docetaxel has been widely used in the treatment of several cancers, including adenocarcinoma of the prostate gland. As docetaxel is insoluble in water, it must be administered with polysorbate 80 and ethanol, which are known to cause hypersensitivity reactions. Premedication with corticosteroids and antihistamines is advocated prior to docetaxel administration; however, toxicities, occasionally fatal, have been reported, even with corticosteroid premedication. We herein report the case of a patient with adenocarcinoma of the prostate, with bone metastasis and an Eastern Cooperative Oncology Group performance status of <2, who developed an allergic reaction to conventional docetaxel (Taxotere), despite being premedicated with corticosteroids and antihistamines. The patient was managed with corticosteroids and antihistamines, and was later started on Doceaqualip, a nanosomal docetaxel lipid suspension. Doceaqualip was well-tolerated by the patient and 5 cycles were subsequently administered, without any adverse reactions. Adenocarcinoma also regressed, as evidenced by positron emission tomography/computed tomography.

View Figures

View References

1	Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU and Hortobagyi GN: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 13:2886–2894. 1995.PubMed/NCBI
2	Pronk LC, Stoter G and Verweij J: Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev. 21:463–478. 1995. View Article : Google Scholar : PubMed/NCBI
3	Hortobagyi GN and Kris MG: Expanding horizons: An update on the use of docetaxel in non-small cell lung, ovarian, and breast cancer. Semin Oncol. 29(3): Suppl 12. S1–S3. 2002. View Article : Google Scholar
4	Hennenfent KL and Govindan R: Novel formulations of taxanes: A review. Old winein a new bottle? Ann Oncol. 17:735–749. 2006. View Article : Google Scholar : PubMed/NCBI
5	Masini E, Planchenault J, Pezziardi F, Gautier P and Gagnol JP: Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: Correlation with its hypotensive action in the dog. Agents Actions. 16:470–477. 1985. View Article : Google Scholar : PubMed/NCBI
6	Loos WJ, Baker SD, Verweij J, Boonstra JG and Sparreboom A: Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins. Clin Pharmacol Ther. 74:364–371. 2003. View Article : Google Scholar : PubMed/NCBI
7	Tije AJ, Verweij J, Loos WJ and Sparreboom A: Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet. 42:665–685. 2003. View Article : Google Scholar : PubMed/NCBI
8	Esmaeili F, Dinarvand R, Ghahremani MH, Amini M, Rouhani H, Sepehri N, Ostad SN and Atyabi F: Docetaxel-albumin conjugates: Preparation, in vitro evaluation and biodistribution studies. J Pharm Sci. 98:2718–2730. 2009. View Article : Google Scholar : PubMed/NCBI
9	Feng SS, Mei L, Anitha P, Gan CW and Zhou W: Poly (lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials. 30:3297–3306. 2009. View Article : Google Scholar : PubMed/NCBI
10	Sheikh S, Ali SM, Ahmad MU, Ahmad A, Mushtaq M, Paithankar M, Mandal J, Saptarishi D, Sehgal A, Maheshwari K and Ahmad I: Nanosomal Amphotericin B is an efficacious alternative to Ambisome for fungal therapy. Int J Pharm. 397:103–108. 2010. View Article : Google Scholar : PubMed/NCBI
11	Ali SM, Ahmad A, Sheikh S, Ahmad MU, Rane RC, Kale P, Paithankar M, Saptarishi D, Sehgal A, Maheshwari K and Ahmad I: Polyoxyl 60 hydrogenated castor oil free nanosomal formulation of immunosuppressant Tacrolimus: Pharmacokinetics, safety, and tolerability in rodents and humans. Int Immunopharmacol. 10:325–330. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hwang HY, Kim IS, Kwon IC and Kim YH: Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release. 128:23–31. 2008. View Article : Google Scholar : PubMed/NCBI
13	Liu B, Yang M, Li R, Ding Y, Qian X, Yu L and Jiang X: The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm. 69:527–534. 2008. View Article : Google Scholar : PubMed/NCBI
14	Du W, Hong L, Yao T, Yang X, He Q, Yang B and Hu Y: Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg Med Chem. 15:6323–6330. 2007. View Article : Google Scholar : PubMed/NCBI
15	De Jong WH and Borm PJ: Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine. 3:133–149. 2008. View Article : Google Scholar : PubMed/NCBI
16	Farokhzad OC and Langer R: Impact of nanotechnology on drug delivery. ACS Nano. 3:16–20. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kipp JE: The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 284:109–122. 2004. View Article : Google Scholar : PubMed/NCBI
18	Ahmad A, Sheikh S, Taran R, Srivastav SP, Prasad K, Rajappa SJ, Kumar V, Gopichand M, Paithankar M, Sharma M, et al: Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients. Clin Breast Cancer. 14:177–181. 2014. View Article : Google Scholar : PubMed/NCBI
19	De Jong WH and Borm PJ: Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine. 3:133–149. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kipp JE: The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 284:109–122. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, et al: Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 30:1534–1540. 2012. View Article : Google Scholar : PubMed/NCBI
22	Urquhart LM: Taxanes as a first-line systemic treatment in metastatic breast cancer. Clin J Oncol Nurs. 17:(Suppl). S15–S21. 2013. View Article : Google Scholar
23	Norris LB, Qureshi ZP, Bookstaver PB, Raisch DW, Sartor O, Chen H, Chen F and Bennett CL: Polysorbate 80 hypersensitivity reactions: A renewed call to action. Commun Oncol. 7:425–428. 2010. View Article : Google Scholar
24	Yoo KE, Kang RY, Lee JY, Lee YJ, Suh SY, Kim KS, Kim HS, Lee SH and Lee BK: Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy. Support Care Cancer. 23:1969–1977. 2015. View Article : Google Scholar : PubMed/NCBI
25	Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, et al: Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study. J Clin Oncol. 27:4522–4529. 2009. View Article : Google Scholar : PubMed/NCBI
26	Karlsson CT, Wiklund F, Grönberg H, Bergh A and Melin B: Risk of prostate cancer after trans urethral resection of BPH: A cohort and nested case-control study. Cancers (Basel). 3:4127–4138. 2011. View Article : Google Scholar : PubMed/NCBI